Tarsus Pharmaceuticals, Inc.
Isoxazoline parasiticide formulations and methods for treating blepharitis

Last updated:

Abstract:

Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.

Status:
Grant
Type:

Utility

Filling date:

5 Mar 2021

Issue date:

14 Dec 2021